<DOC>
	<DOCNO>NCT00227513</DOCNO>
	<brief_summary>This phase I trial study side effect best dose vorinostat bortezomib treat patient metastatic unresectable solid tumor . Drugs use chemotherapy , vorinostat , work different way stop growth tumor cell , either kill cell stop dividing . Bortezomib may stop growth tumor cell block enzymes need cell growth . Giving vorinostat together bortezomib may kill tumor cell .</brief_summary>
	<brief_title>Vorinostat Bortezomib Treating Patients With Metastatic Unresectable Solid Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose vorinostat ( SAHA ) bortezomib patient metastatic unresectable solid tumor . SECONDARY OBJECTIVES : I . Determine pharmacokinetics antitumor activity regimen patient . II . Determine toxic effect regimen patient . OUTLINE : This dose-escalation study . Patients receive oral vorinostat ( SAHA ) twice daily day 1-14 step A . Patients receive oral vorinostat ( SAHA ) twice daily day 1-4 8-11 Step B bortezomib IV 3-5 second day 2 , 5 , 9 , 12 first course day 1 , 4 , 8 , 11 subsequent course step A B . Courses repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 1-6 patient receive escalate dos bortezomib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Up 6 additional patient receive bortezomib MTD . Subsequent cohort 3-6 patient receive escalate dos SAHA MTD drug determine .</detailed_description>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Histologically confirm malignancy , metastatic unresectable disease Standard curative palliative measure exist OR longer effective Measurable evaluable disease No known brain metastasis ECOG 02 OR Karnofsky 60100 % Life expectancy &gt; 12 week WBC ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Bilirubin normal AST ALT ≤ 2.5 time upper limit normal Creatinine normal OR creatinine clearance ≥ 60 mL/min No history myocardial infarction No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia No severe pulmonary disease require oxygen Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 28 day study participation No history allergic reaction attribute compound similar chemical biological composition study drug agents No preexist neuropathy ≥ grade 2 No uncontrolled illness No ongoing active infection No psychiatric illness social situation would preclude study compliance More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover No prior radiotherapy &gt; 25 % bone marrow At least 4 week since prior radiotherapy recover At least 2 week since prior valproic acid No prior bortezomib No concurrent enzymeinducing anticonvulsant agent No concurrent investigational agent No concurrent combination antiretroviral therapy HIVpositive patient No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>